Literature DB >> 33030667

Subjective and objective cognitive functioning among patients with breast cancer: effects of chemotherapy and mood symptoms.

Yen-Hsuan Hsu1,2, Vincent Chin-Hung Chen3,4, Ching-Chuan Hsieh5,6, Yi-Ping Weng7, Ya-Ting Hsu3, Han-Pin Hsiao3, Wen-Ke Wang8, Hong-Ming Chen3, Jun-Cheng Weng3,9, Shu-I Wu10,11, Michael Gossop12.   

Abstract

BACKGROUND: Previous findings regarding declines in cognitive functioning among patients with breast cancer (BC) before and after chemotherapy have been inconsistent. The present study explored the effect of BC and cancer-related chemotherapies on cognitive functioning.
METHODS: A cross-sectional design was adopted to compare BC patients before their chemotherapy treatment, BC patients 3 ~ 9 months after the completion of chemotherapy, and noncancer controls. Evaluations of cognitive functioning included subjective and objective dimensions, with focus on memory, executive functioning, attention, and language. ANCOVA and Pearson's correlation analysis were used to examine the relationship among cancer, chemotherapy, cognitive performance, and psychological distress.
RESULTS: After adjustment for intelligence quotient, anxiety, and depression, we found significant differences in the Semantic Association of Verbal Fluency between post-chemotherapy (C/T) patients and noncancer controls. Specifically, post-C/T patients scored lower than controls (p = 0.03, η2 = 0.07). No significant differences were found in other objective cognitive measures. However, both subjective and objective cognitive scores were significantly associated with depression, anxiety, and fatigue. In BC patients, levels of anxiety were positively correlated with measures of executive function. Among pre-C/T patients, self-perceived interference by fatigue was positively associated with better performances in some of the objective cognitive measures.
CONCLUSION: Our findings suggest cognitive impairments in the domain of executive functioning among patients with BC who received chemotherapy. Providing relevant suggestions or strategies of managements for these negative consequences may help increase the long-term quality of life of patients with BC.

Entities:  

Keywords:  Cancer; Cognitive functioning; Neuropsychological testing

Mesh:

Year:  2020        PMID: 33030667     DOI: 10.1007/s12282-020-01168-y

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  28 in total

Review 1.  An update on cancer- and chemotherapy-related cognitive dysfunction: current status.

Authors:  Michelle C Janelsins; Sadhna Kohli; Supriya G Mohile; Kenneth Usuki; Tim A Ahles; Gary R Morrow
Journal:  Semin Oncol       Date:  2011-06       Impact factor: 4.929

Review 2.  Executive functioning impairment in women treated with chemotherapy for breast cancer: a systematic review.

Authors:  Christie Yao; Lori J Bernstein; Jill B Rich
Journal:  Breast Cancer Res Treat       Date:  2017-07-13       Impact factor: 4.872

Review 3.  Cognitive impairment following hormone therapy: current opinion of research in breast and prostate cancer patients.

Authors:  Lisa M Wu; Ali Amidi
Journal:  Curr Opin Support Palliat Care       Date:  2017-03       Impact factor: 2.302

Review 4.  Chemotherapy and Cognitive Function in Breast Cancer Patients: The So-Called Chemo Brain.

Authors:  Kerstin Hermelink
Journal:  J Natl Cancer Inst Monogr       Date:  2015-05

Review 5.  Brain vulnerability to chemotherapy toxicities.

Authors:  Tim A Ahles
Journal:  Psychooncology       Date:  2012-10-01       Impact factor: 3.894

6.  Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients.

Authors:  Sanne B Schagen; Martin J Muller; Willem Boogerd; Gideon J Mellenbergh; Frits S A M van Dam
Journal:  J Natl Cancer Inst       Date:  2006-12-06       Impact factor: 13.506

7.  Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study.

Authors:  Roberta De Angelis; Milena Sant; Michel P Coleman; Silvia Francisci; Paolo Baili; Daniela Pierannunzio; Annalisa Trama; Otto Visser; Hermann Brenner; Eva Ardanaz; Magdalena Bielska-Lasota; Gerda Engholm; Alice Nennecke; Sabine Siesling; Franco Berrino; Riccardo Capocaccia
Journal:  Lancet Oncol       Date:  2013-12-05       Impact factor: 41.316

8.  Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer.

Authors:  Jeffrey S Wefel; Angele K Saleeba; Aman U Buzdar; Christina A Meyers
Journal:  Cancer       Date:  2010-07-15       Impact factor: 6.860

9.  Neuropsychological functioning and quality of life during the first year after completing chemotherapy for breast cancer.

Authors:  Stephanie A Reid-Arndt; Catherine Hsieh; Michael C Perry
Journal:  Psychooncology       Date:  2010-05       Impact factor: 3.894

10.  5-fluorouracil-induced leukoencephalopathy in patients with breast cancer.

Authors:  S M Choi; S H Lee; Y S Yang; B C Kim; M K Kim; K H Cho
Journal:  J Korean Med Sci       Date:  2001-06       Impact factor: 2.153

View more
  3 in total

1.  Depression and survival of breast cancer patients: A protocol for systematic review and meta-analysis.

Authors:  Guanghui Zhu; Juan Li; Jie Li; Xinmiao Wang; Minghao Dai; Jiayang Chen
Journal:  Medicine (Baltimore)       Date:  2020-11-25       Impact factor: 1.889

2.  The COMT Genetic Factor Regulates Chemotherapy-Related Prospective Memory Impairment in Survivors With HER2-/+ Breast Cancer.

Authors:  Wen Li; Qianqian Zhang; Yinlian Cai; Tingting Chen; Huaidong Cheng
Journal:  Front Oncol       Date:  2022-02-08       Impact factor: 6.244

3.  Effects of Cancer, Chemotherapy, and Cytokines on Subjective and Objective Cognitive Functioning Among Patients with Breast Cancer.

Authors:  Vincent Chin-Hung Chen; Chin-Kuo Lin; Han-Pin Hsiao; Bor-Show Tzang; Yen-Hsuan Hsu; Shu-I Wu; Robert Stewart
Journal:  Cancers (Basel)       Date:  2021-05-24       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.